Table 1.
| A: Characteristics of all gliomas (WHO grades II-IV) implanted | ||
| Viable (N=94) | Non-viable (N=167) | |
| WHO Histologic Grade (at Implant) | ||
| II | 0 | 9 (5) |
| III | 0 | 50 (30) |
| IV | 94 (100) | 107 (64) |
| Indeterminate | 0 | 1 (1) |
| Diagnosis† | ||
| Glioblastoma, IDH-mutant (WHO IV) | 2 (2) | 11 (7) |
| Glioblastoma, NOS* (WHO IV) | 0 | 37 (22) |
| Glioblastoma, IDH-wildtype (WHO IV) | 91 (97) | 59 (35) |
| Gliosarcoma‡ | 4 | 3 |
| Glioblastoma with primitive neuronal component‡ | 1 | 0 |
| Diffuse midline glioma, H3 K27M-mutant (WHO IV) | 1 (1) | 0 |
| Other diagnoses** | 0 | 60 (36) |
| B: Patient characteristics of WHO grade IV gliomas implanted | ||
| Viable N=94 | Non-Viable N=107 | |
| Mean age, years (range) | 58.3 (21 – 84) | 56.5 (16 – 85) |
| Male, n (%) | 57 (61) | 65 (61) |
| Tumor Type Implanted | ||
| Primary | 60 (64) | 60 (56) |
| Recurrent | 27 (29) | 40 (37) |
| Recurrent in progression from lower-grade | 7 (7) | 7 (6) |
| Therapy prior to engraftment | ||
| None | 60 (64) | 60 (56) |
| RT, TMZ | 12 (13) | 20 (19) |
| RT, TMZ, other therapy | 19 (20) | 25 (23) |
| RT | 0 | 0 (0) |
| Other therapy combination | 3 (3) | 2 (2) |